Orencia remission Induction and Outcome Navigation Study

Orencia remission Induction and Outcome Navigation Study - ORION Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004137

Enrollment

Registered

2010-09-01

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who give a full consent to this study 2) Patients with rheumatoid arthritis having joined in studies IM101071 and IM101129 and treated with abatacept at entry. 3) Patients whose DAS28-CRP is less than 2.3 at the time of entry

Exclusion criteria

Exclusion criteria: Patients who are inadequate by investigator 's decision

Design outcomes

Primary

Measure	Time frame
Rate of the discontinuation of abatacept at one year after discontinuation of abatacept	—

Secondary

Measure	Time frame
1) Change in remission rate (DAS28-CRP) 2) X ray 3) Change in HAQ 4) The mean of re-administration time 5) Stratified analysis of remission conditions 6) Efficacy and safety of re-administration of abatacept after recurrence	—

Countries

Japan

Outcome results